BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Zura Bio (ZURA)Zura BioEarnings

Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027 Cash and cash

Related news

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

INMBINmune Bio2026-07-31 11:00 EST

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

XFORX4 Pharmaceuticals2026-08-06 20:15 EST

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CLDXCelldex Therapeutics2026-08-06 20:01 EST

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

ACRSAclaris Therapeutics2026-08-06 10:59 EST

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

View all latest news

Zura Bio

Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...

Recent company news

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ZURAZura Bio2026-05-14 11:30 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-05-13 11:30 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-05-04 20:05 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
5.71 USD
Market cap
389.01M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States